


Correction

# Correction: Immunomodulator Clarithromycin Enhances Mucosal and Systemic Immune Responses and Reduces Re-Infection Rate in Pediatric Patients with Influenza Treated with Antiviral Neuraminidase Inhibitors: A Retrospective Analysis

The PLOS ONE Staff

There are errors in Figure 1 and in the last two sentences of the fourth paragraph of the Results section.

The labeling of the number of patients and the re-infection rates are incorrect in Figure 1. Please see the corrected Figure 1 here.



**Figure 1. Re-infection rate in 2009/2010 season.** The re-infection rate in 2009/2010 season in children who were infected with IAV during the 2008/2009 season and either untreated or treated with OSV, OSV+CAM, ZNV and ZNV+CAM. Data show the percentage of infected children in each group. \* $P < 0.05$ , \* \* $P < 0.01$ , versus no treatment (Fisher's exact test with Bonferroni correction). doi:10.1371/journal.pone.0070060.g001

There are errors in the last two sentences of the fourth paragraph of the Results section. The corrected sentence should read: "However, the proportions of children treated the previous year with OSV and ZNV who developed re-infection in 2009-2010 were significantly higher at 37.3% and 57.5%, respectively ( $P < 0.01$ ), than those of the no-treatment group. The combination treatment of CAM plus OSV and CAM plus ZNV tended to reduce the re-infection rate to 17.6% and 33.3%, respectively, albeit insignificantly."

## Reference

- Shinahara W, Takahashi E, Sawabuchi T, Arai M, Hirotsu N, et al. (2013) Immunomodulator Clarithromycin Enhances Mucosal and Systemic Immune Responses and Reduces Re-Infection Rate in Pediatric Patients with Influenza Treated with Antiviral Neuraminidase Inhibitors: A Retrospective Analysis. PLoS ONE 8(7): e70060. doi:10.1371/journal.pone.0070060

**Citation:** The PLOS ONE Staff (2014) Correction: Immunomodulator Clarithromycin Enhances Mucosal and Systemic Immune Responses and Reduces Re-Infection Rate in Pediatric Patients with Influenza Treated with Antiviral Neuraminidase Inhibitors: A Retrospective Analysis. PLoS ONE 9(7): e104573. doi:10.1371/journal.pone.0104573

**Published:** July 31, 2014

**Copyright:** © 2014 The PLOS ONE Staff. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.